EN DE

Central Proteina Prima Tbk (CPRO) Fair Value & Analysis

Consumer Defensive · ID · Market cap 3.0T IDR

CP Central Proteina Prima Tbk CPRO · JK
Price50.00 IDR
Fair Value99.09 IDR
Upside+98.2%
Quality55/100
Watch Central Proteina Prima Tbk for free, get notified when fair value or trend changes. Watch for free
Mixed Growth
Thin margins · 3.6% net margin
Low debt · generates free cash flow
Ranks above peers (11/14)
Narrow moat 43/100
Evidence: High Range 57.58 IDR – 140.66 IDR Share as image

Fair value as of: Aug 13, 2026

From 25 valuation models · updated 6 days ago

Fair value updated Aug 13, 2026, revised from 125.94 IDR to 99.09 IDR (−21.3%) since Jul 16, 2026.

A solid business, screening 98% undervalued on our models.

Fair value for all 35,000+ stocks, review alerts and the diversification check: 14 days of Pro free, no card.

What matters now

  • The price is below even our cautious bear case (57.58 IDR). The market is more pessimistic than our downside scenario.
  • Solid quality (55/100) at a price below fair value, the discount is the argument here, not the business quality.
  • A fairly wide model range (57.58 IDR to 140.66 IDR) leaves room in how you read the outcome.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

126.00 IDR 50.00 IDR Fair Value 99.09 IDR Mar 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range 50.00 IDR – 126.00 IDR · fair‑value band 57.58 IDR – 140.66 IDR · the 50.00 IDR price screens below the 99.09 IDR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Central Proteina Prima Tbk (CPRO) currently trades at 50.00 IDR, while our model-based Fair Value estimate is 99.09 IDR, implying the stock looks roughly 98.2% undervalued today. The Quality Score stands at 55/100 (solid quality), in the Consumer Defensive sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.

Over the trailing twelve months, Central Proteina Prima Tbk generated revenue of 10.0T IDR at a net margin of 3.6%. Revenue grew 3.1% year over year. It earns a return on equity of 9.6%. Net debt stands at 1.5T IDR. Fundamentals as of Aug 13, 2026

Our scenario range runs from 57.58 IDR (bear case) to 140.66 IDR (bull case); at 50.00 IDR, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 43% below its 52-week high, currently below its 200-day average. For context, the median of 10 Consumer Defensive peers we cover trades at 97% fair-value upside, at 98%, CPRO screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF 29.63 IDR 41.62 IDR 58.87 IDR 80
Residual Income 58.37 IDR 69.44 IDR 158.92 IDR 76
Rev-Margin DCF 92.38 IDR 155.57 IDR 222.36 IDR 74
All 25 models by family
DCF Models
FCF DCF 28.74 IDR 41.53 IDR 60.74 IDR 38
Owner Earnings 68.61 IDR 100.48 IDR 148.34 IDR 31
5Y Revenue Exit 92.38 IDR 156.42 IDR 236.78 IDR 39
5Y EBITDA Exit 107.08 IDR 182.59 IDR 267.97 IDR 41
5Y P/E Exit 75.25 IDR 125.94 IDR 176.83 IDR 38
10Y Revenue Exit 65.21 IDR 119.10 IDR 188.21 IDR 36
10Y EBITDA Exit 78.60 IDR 137.20 IDR 211.48 IDR 37
10Y P/E Exit 58.25 IDR 98.01 IDR 143.47 IDR 35
Earnings-Based
Graham-Dodd 48.36 IDR 113.90 IDR 146.63 IDR 54
PEG = 1.0 19.61 IDR 28.02 IDR 36.43 IDR 46
EPV 113.59 IDR 133.28 IDR 150.79 IDR 59
Dividend Discount
Gordon GGM 0.0500 IDR 0.0900 IDR 0.1400 IDR 70
DDM Multi-Stage 0.0500 IDR 0.0700 IDR 0.1000 IDR 61
Multiples
P/E Multiple 112.01 IDR 149.34 IDR 186.68 IDR 63
P/S Multiple 90.67 IDR 120.90 IDR 151.12 IDR 58
P/B Multiple 90.67 IDR 120.90 IDR 151.12 IDR 55
EV/EBIT 187.72 IDR 249.63 IDR 311.53 IDR 53
EV/EBITDA 169.79 IDR 225.71 IDR 281.63 IDR 54
EV/Revenue 134.56 IDR 191.36 IDR 248.17 IDR 43
Asset-Based
NCAV (Graham) 31.79 IDR 42.60 IDR 63.59 IDR 50
Growth DCF
Growth DCF 29.63 IDR 41.62 IDR 58.87 IDR 80
Rev-Margin DCF 92.38 IDR 155.57 IDR 222.36 IDR 74
Economic Profit
Residual Income 58.37 IDR 69.44 IDR 158.92 IDR 76
ROIC Compounder 118.67 IDR 147.24 IDR 179.23 IDR 72
Growth Earnings
Growth-Adj P/E 84.83 IDR 121.18 IDR 157.54 IDR 68

Widest divergence: Multiples (149.34 IDR) versus Dividend Discount (0.0700 IDR). Highest evidence: Growth DCF (80).

Notify me when CPRO reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 10.0T IDR
Revenue growth (YoY) +3.1%
Net margin 3.6%
Return on equity 9.6%
Free cash flow 142B IDR FY2025
P/E ratio 8.2 as of Jun 9, 2026
More key figures
Operating margin 7.2%
EPS (TTM) 6.10 IDR
EPS growth (YoY) -37.5%
Net debt 1.5T IDR FY2025

Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 55/100

Of which business quality 53 · Market factors (momentum, volatility) 32

Profitability 54
Margins and returns on capital today
Quality Growth 55
Are margins and returns improving?
Cashflow 19
Earnings quality: real cash, not paper profit
Fin. Strength 46
Balance sheet, leverage, solvency risk
Investment 86
Disciplined investing over empire-building
Low Volatility 52
Calm price path (market factor)
Momentum 29
Price trend over the last 3–12 months (market factor)
52W Momentum 16
Distance to the 52-week high (market factor)
Net Issuance 82
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

PT Central Proteina Prima Tbk, together with its subsidiaries, operates as an integrated aquaculture shrimp and food producer company in Indonesia, India, Vietnam, China, Japan, the United States, Canada, the United Kingdom, Belgium, France, the Netherlands, Germany, and New Zealand. The company operates through Feeds, Food Products, and Others segments.

Full company description

PT Central Proteina Prima Tbk, together with its subsidiaries, operates as an integrated aquaculture shrimp and food producer company in Indonesia, India, Vietnam, China, Japan, the United States, Canada, the United Kingdom, Belgium, France, the Netherlands, Germany, and New Zealand. The company operates through Feeds, Food Products, and Others segments. It engages in the industry, livestock and agriculture, farming, hatchery, and trading and services, as well as production and trading of shrimp, fish feeds and pet food. The company also offers shrimp feed, fish feed, cat food, dog food, fish food, bird food, rabbit food, probiotic products, fish additives, disinfectants, fish hatchery, shrimp hatchery, medicines for shrimp and fish, and probiotic for shrimp medicines, as well as is involved in the cold storage and trading of shrimp, and an investment holding business. The company was formerly known as PT Central Proteinaprima Tbk and changed its name to PT Central Proteina Prima Tbk in June 2014. The company was incorporated in 1980 and is headquartered in Jakarta Selatan, Indonesia.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Central Proteina Prima Tbk reported revenue of 9.9T IDR in FY2025 versus 8.0T IDR in FY2021, a compound +5.5%/yr. Reported net income was 424B IDR in FY2025, compounding −33.8%/yr from FY2021.

Growth Quality 48/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2025)
9.9T IDR
Latest YoY
+7.2%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+6.5%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+5.6%
Avg. growth/yr (25Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+3.1%
Revenue +5.5%/yr
FY21 8.0T IDR
FY22 8.2T IDR
FY23 9.0T IDR
FY24 9.3T IDR
FY25 9.9T IDR
Net income −33.8%/yr
FY21 2.2T IDR
FY22 374B IDR
FY23 401B IDR
FY24 320B IDR
FY25 424B IDR

Watch CPRO: get an alert when its fair value changes →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Central Proteina Prima Tbk Fair Value". https://www.fairvalue-calculator.com/stock/CPRO

Peer Group

Farm Products · 302 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 55 · Above median
Fair Value upside +98% · Top 25%
Return on equity (TTM) 10% · Above median
Return on assets 7% · Top 25%
Net margin (TTM) 4% · Above median
Operating margin (TTM) 7% · Above median
Revenue growth 3% · Below median
Dividend yield (TTM) 0.0% · Bottom 25%
Debt / equity 0.01× · Lower than 75% of peers

Valuation Multiples vs Farm Products median · lower = cheaper

P/E (TTM) 8.2× · Cheaper than median
P/B 0.79× · Pricier than median
P/S (TTM) 0.30× · Cheaper than median
P/FCF 0.0× · Cheaper than 75% of peers
EV/EBITDA 3.2× · Cheaper than median

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE100 · sector 28
FUTURE16 · sector 20
PAST38 · sector 18
HEALTH100 · sector 94
DIVIDEND0 · sector 47

Insider activity: 35/100

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Farm Products stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Stock Price Fair Value vs Fair Value
Muyuan Foods Group 002714 ¥40.15 ¥47.42 +18%
Charoen Pokphand Foods Public Company CPF 21.90 THB 43.24 THB +97%
PT Charoen Pokphand Indonesia Tbk, CPIN 2,960 IDR 6,818 IDR +130%
PT Triputra Agro Persada Tbk TAPG 1,805 IDR 3,087 IDR +71%
PT FAP Agri Tbk FAPA 7,350 IDR 6,420 IDR -13%
PT Japfa Comfeed Indonesia Tbk JPFA 2,260 IDR 6,974 IDR +209%
PT Jhonlin Agro Raya Tbk JARR 1,890 IDR 610.80 IDR -68%
PT Nusantara Sawit Sejahtera Tbk NSSS 860.00 IDR 402.24 IDR -53%
PT Sinar Mas Agro Resources and Technology Tbk SMAR 5,625 IDR 16,227 IDR +188%
PT Dharma Satya Nusantara Tbk DSNG 1,320 IDR 2,696 IDR +104%

Compare Central Proteina Prima Tbk with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Consumer Defensive stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Central Proteina Prima Tbk (CPRO) overvalued or undervalued?
As of Aug 13, 2026, our model estimates a fair value of 99.09 IDR versus a price of 50.00 IDR, about +98% (undervalued).
What is the fair value of CPRO?
Our model-based fair value for Central Proteina Prima Tbk is 99.09 IDR (as of Aug 13, 2026), built from audited fundamentals. The current price: 50.00 IDR.
What is the quality score of CPRO?
Central Proteina Prima Tbk has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Central Proteina Prima Tbk (CPRO)?
Central Proteina Prima Tbk reported trailing-twelve-month revenue of about 10.0T IDR (latest available figure, as of Aug 13, 2026).
What is the net profit margin of CPRO?
The net profit margin of Central Proteina Prima Tbk is about 3.6%, meaning it keeps roughly 3.6% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Central Proteina Prima Tbk and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.